Clene Inc.
Close on Oct 19, 2026
- Market cap
- $40.74M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | $90.00K | $-1.08 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $15.00K | $-0.69 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $15.00K | $-0.85 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $27.00K | $-0.78 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $87.00K | $-1.22 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
Press releases
Announcements Clene filed with the SEC
CLENE ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING
Material agreement · Other events · EX-99.1 to Form 8-K
CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CLENE ANNOUNCES BIOMARKER ANALYSES TO BE INCLUDED IN
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CLENE REPORTS First QUARTER 2026 FINANCIAL RESULTS
Material agreement · Results of operations · EX-99.1 to Form 8-K
CLENE ANNOUNCES $7 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK
Material agreement · Other events · EX-99.1 to Form 8-K
CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CLENE REPORTS FULL YEAR 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
CLENE ISSUES STOCKHOLDER LETTER HIGHLIGHTING
Other events · EX-99.1 to Form 8-K
CLENE ANNOUNCES REGISTERED DIRECT OFFERING OF OVER $28 MILLION
Material agreement · Other events · EX-99.1 to Form 8-K
CLENE ANNOUNCES ADDITIONAL CNM-Au8 BIOMARKER DATA
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
CLENE ANNOUNCES STATISTICALLY SIGNIFICANT ALS
Other events · EX-99.1 to Form 8-K
CLENE REPORTS Third QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CLENE PRESENTS NEW CLINICAL DATA AT ECTRIMS 2025 MEETING
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CLENE REPORTS Second QUARTER 2025 FINANCIAL RESULTS
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
FOLLOWING CONSTRUCTIVE FDA TYPE-C MEETING ON
Other events · EX-99.1 to Form 8-K
CLENE REPORTS First QUARTER 2025 FINANCIAL RESULTS
Results of operations · Listing notice · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CLENE PRESENTS EVIDENCE OF REMYELINATION AND NEURONAL
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
CLENE REPORTS FULL YEAR 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
CLENE DEMONSTRATES STRENGTHENED ALS SURVIVAL BENEFIT
Other events · EX-99.1 to Form 8-K
CLENE IMPROVES CASH POSITION AND RUNWAY
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
CLENE REPORTS Third QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
CLENE ANNOUNCES $7.3 MILLION REGISTERED DIRECT
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
CLENE GRANTED IN-PERSON MEETING WITH
Other events · EX-99.1 to Form 8-K
CLENE REPORTS Second QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CLENE ANNOUNCES NEW CNM-Au8 ® BIOMARKER AND
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Clene Announces 1-for-20 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K